Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Sep 8, 2023

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

Sep 6, 2023

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 21, 2023

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

Aug 14, 2023

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

Jul 17, 2023

ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline

Jul 14, 2023

ProMIS Announces Completion of Continuance

Jul 10, 2023

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

Jun 30, 2023

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

Jun 29, 2023

CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

May 15, 2023

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …25
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy